Skip to main content
Erschienen in: Heart Failure Reviews 3/2018

17.02.2018

Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance

verfasst von: Evangelos Oikonomou, Konstantinos Mourouzis, Petros Fountoulakis, Georgios Angelos Papamikroulis, Gerasimos Siasos, Alexis Antonopoulos, Georgia Vogiatzi, Sotiris Tsalamadris, Manolis Vavuranakis, Dimitris Tousoulis

Erschienen in: Heart Failure Reviews | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Heart failure (HF) is a common cardiac syndrome, whose pathophysiology involves complex mechanisms, some of which remain unknown. Diabetes mellitus (DM) constitutes not only a glucose metabolic disorder accompanied by insulin resistance but also a risk factor for cardiovascular disease and HF. During the last years though emerging data set up, a bidirectional interrelationship between these two entities. In the case of DM impaired calcium homeostasis, free fatty acid metabolism, redox state, and advance glycation end products may accelerate cardiac dysfunction. On the other hand, when HF exists, hypoperfusion of the liver and pancreas, b-blocker and diuretic treatment, and autonomic nervous system dysfunction may cause impairment of glucose metabolism. These molecular pathways may be used as therapeutic targets for novel antidiabetic agents. Peroxisome proliferator-activated receptors (PPARs) not only improve insulin resistance and glucose and lipid metabolism but also manifest a diversity of actions directly or indirectly associated with systolic or diastolic performance of left ventricle and symptoms of HF. Interestingly, they may beneficially affect remodeling of the left ventricle, fibrosis, and diastolic performance but they may cause impaired water handing, sodium retention, and decompensation of HF which should be taken into consideration in the management of patients with DM. In this review article, we present the pathophysiological data linking HF with DM and we focus on the molecular mechanisms of PPARs agonists in left ventricle systolic and diastolic performance providing useful insights in the molecular mechanism of this class of metabolically active regiments.
Literatur
2.
Zurück zum Zitat Siasos G, Tousoulis D, Tourikis P, Mazaris S, Zakynthinos G, Oikonomou E, Kokkou E, Kollia C, Stefanadis C (2013) MicroRNAs in cardiovascular therapeutics. Curr Top Med Chem 13:1605–1618PubMedCrossRef Siasos G, Tousoulis D, Tourikis P, Mazaris S, Zakynthinos G, Oikonomou E, Kokkou E, Kollia C, Stefanadis C (2013) MicroRNAs in cardiovascular therapeutics. Curr Top Med Chem 13:1605–1618PubMedCrossRef
4.
Zurück zum Zitat Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes A, European Association for the Study of D (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289–2304PubMedCrossRef Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes A, European Association for the Study of D (2005) The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28:2289–2304PubMedCrossRef
5.
Zurück zum Zitat DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194PubMedCrossRef DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194PubMedCrossRef
6.
Zurück zum Zitat Kaplan NM (1989) The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514–1520PubMedCrossRef Kaplan NM (1989) The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514–1520PubMedCrossRef
7.
Zurück zum Zitat Gu K, Cowie CC, Harris MI (1999) Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291–1297PubMedCrossRef Gu K, Cowie CC, Harris MI (1999) Diabetes and decline in heart disease mortality in US adults. JAMA 281:1291–1297PubMedCrossRef
8.
Zurück zum Zitat Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:1810–1852. https://doi.org/10.1161/CIR.0b013e31829e8807 PubMedCrossRef Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:1810–1852. https://​doi.​org/​10.​1161/​CIR.​0b013e31829e8807​ PubMedCrossRef
10.
Zurück zum Zitat Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29–34PubMedCrossRef Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29–34PubMedCrossRef
11.
Zurück zum Zitat Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, Gheorghiade M, O'Connor CM, Sun JL, Yancy CW, Young JB, Fonarow GC (2007) Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 154(277):e271–e278. https://doi.org/10.1016/j.ahj.2007.05.001 CrossRef Greenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, Gheorghiade M, O'Connor CM, Sun JL, Yancy CW, Young JB, Fonarow GC (2007) Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 154(277):e271–e278. https://​doi.​org/​10.​1016/​j.​ahj.​2007.​05.​001 CrossRef
12.
Zurück zum Zitat Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884PubMedCrossRef Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884PubMedCrossRef
13.
Zurück zum Zitat Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL, Investigators RR (2015) Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 132:923–931. https://doi.org/10.1161/CIRCULATIONAHA.114.014796 PubMedCrossRef Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL, Investigators RR (2015) Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 132:923–931. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​114.​014796 PubMedCrossRef
15.
Zurück zum Zitat Wong YW, Thomas L, Sun JL, McMurray JJ, Krum H, Hernandez AF, Rutten GE, Leiter LA, Standl E, Haffner SM, Mazzone T, Martinez FA, Tognoni G, Giles T, Califf RM (2013) Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research study. Circ Heart Fail 6:203–210. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000086 PubMedCrossRef Wong YW, Thomas L, Sun JL, McMurray JJ, Krum H, Hernandez AF, Rutten GE, Leiter LA, Standl E, Haffner SM, Mazzone T, Martinez FA, Tognoni G, Giles T, Califf RM (2013) Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research study. Circ Heart Fail 6:203–210. https://​doi.​org/​10.​1161/​CIRCHEARTFAILURE​.​112.​000086 PubMedCrossRef
16.
Zurück zum Zitat Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation 103:2668–2673PubMedCrossRef Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV (2001) Glycemic control and heart failure among adult patients with diabetes. Circulation 103:2668–2673PubMedCrossRef
19.
Zurück zum Zitat Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, Nodari S, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M, investigators E (2013) Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 15:194–202. https://doi.org/10.1093/eurjhf/hfs153 PubMedCrossRef Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, Nodari S, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M, investigators E (2013) Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 15:194–202. https://​doi.​org/​10.​1093/​eurjhf/​hfs153 PubMedCrossRef
20.
Zurück zum Zitat Ikeda Y, Inomata T, Fujita T, Iida Y, Kaida T, Nabeta T, Ishii S, Maekawa E, Yanagisawa T, Mizutani T, Naruke T, Koitabashi T, Takeuchi I, Ako J (2017) Higher hemoglobin A1c levels are associated with impaired left ventricular diastolic function and higher incidence of adverse cardiac events in patients with nonischemic dilated cardiomyopathy. Heart Vessel 32:446–457. https://doi.org/10.1007/s00380-016-0895-x CrossRef Ikeda Y, Inomata T, Fujita T, Iida Y, Kaida T, Nabeta T, Ishii S, Maekawa E, Yanagisawa T, Mizutani T, Naruke T, Koitabashi T, Takeuchi I, Ako J (2017) Higher hemoglobin A1c levels are associated with impaired left ventricular diastolic function and higher incidence of adverse cardiac events in patients with nonischemic dilated cardiomyopathy. Heart Vessel 32:446–457. https://​doi.​org/​10.​1007/​s00380-016-0895-x CrossRef
22.
Zurück zum Zitat Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, Coats A, Filippatos G, Crespo-Leiro M, Mebazaa A, Piepoli MF, Maggioni AP, Tavazzi L, Registry E-HHFL-T (2017) Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: Results from the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care 40:671–678. https://doi.org/10.2337/dc16-2016 PubMedCrossRef Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, Coats A, Filippatos G, Crespo-Leiro M, Mebazaa A, Piepoli MF, Maggioni AP, Tavazzi L, Registry E-HHFL-T (2017) Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: Results from the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care 40:671–678. https://​doi.​org/​10.​2337/​dc16-2016 PubMedCrossRef
25.
Zurück zum Zitat Glogner S, Rosengren A, Olsson M, Gudbjornsdottir S, Svensson AM, Lind M (2014) The association between BMI and hospitalization for heart failure in 83,021 persons with type 2 diabetes: a population-based study from the Swedish National Diabetes Registry. Diabet Med 31:586–594. https://doi.org/10.1111/dme.12340 PubMedCrossRef Glogner S, Rosengren A, Olsson M, Gudbjornsdottir S, Svensson AM, Lind M (2014) The association between BMI and hospitalization for heart failure in 83,021 persons with type 2 diabetes: a population-based study from the Swedish National Diabetes Registry. Diabet Med 31:586–594. https://​doi.​org/​10.​1111/​dme.​12340 PubMedCrossRef
26.
Zurück zum Zitat Echouffo-Tcheugui JB, Xu H, DeVore AD, Schulte PJ, Butler J, Yancy CW, Bhatt DL, Hernandez AF, Heidenreich PA, Fonarow GC (2016) Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get with the Guidelines-Heart Failure registry. Am Heart J 182:9–20. https://doi.org/10.1016/j.ahj.2016.07.025 PubMedCrossRef Echouffo-Tcheugui JB, Xu H, DeVore AD, Schulte PJ, Butler J, Yancy CW, Bhatt DL, Hernandez AF, Heidenreich PA, Fonarow GC (2016) Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get with the Guidelines-Heart Failure registry. Am Heart J 182:9–20. https://​doi.​org/​10.​1016/​j.​ahj.​2016.​07.​025 PubMedCrossRef
28.
31.
Zurück zum Zitat Li C, Lu C, Zhao X, Chen X (2015) Comparison between myocardial infarction and diabetes mellitus damage caused angiogenesis or energy metabolism. Int J Clin Exp Med 8:22371–22376PubMedPubMedCentral Li C, Lu C, Zhao X, Chen X (2015) Comparison between myocardial infarction and diabetes mellitus damage caused angiogenesis or energy metabolism. Int J Clin Exp Med 8:22371–22376PubMedPubMedCentral
35.
Zurück zum Zitat Winhofer Y, Krssak M, Wolf P, Anderwald CH, Geroldinger A, Heinze G, Baumgartner-Parzer S, Marculescu R, Stulnig T, Wolzt M, Trattnig S, Luger A, Krebs M (2015) Free fatty acid availability is closely related to myocardial lipid storage and cardiac function in hypoglycemia counterregulation. Am J Phys Endocrinol Metab 308:E631–E640. https://doi.org/10.1152/ajpendo.00371.2014 CrossRef Winhofer Y, Krssak M, Wolf P, Anderwald CH, Geroldinger A, Heinze G, Baumgartner-Parzer S, Marculescu R, Stulnig T, Wolzt M, Trattnig S, Luger A, Krebs M (2015) Free fatty acid availability is closely related to myocardial lipid storage and cardiac function in hypoglycemia counterregulation. Am J Phys Endocrinol Metab 308:E631–E640. https://​doi.​org/​10.​1152/​ajpendo.​00371.​2014 CrossRef
37.
Zurück zum Zitat Zhao G, Jeoung NH, Burgess SC, Rosaaen-Stowe KA, Inagaki T, Latif S, Shelton JM, McAnally J, Bassel-Duby R, Harris RA, Richardson JA, Kliewer SA (2008) Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy. Am J Phys Heart Circ Phys 294:H936–H943. https://doi.org/10.1152/ajpheart.00870.2007 CrossRef Zhao G, Jeoung NH, Burgess SC, Rosaaen-Stowe KA, Inagaki T, Latif S, Shelton JM, McAnally J, Bassel-Duby R, Harris RA, Richardson JA, Kliewer SA (2008) Overexpression of pyruvate dehydrogenase kinase 4 in heart perturbs metabolism and exacerbates calcineurin-induced cardiomyopathy. Am J Phys Heart Circ Phys 294:H936–H943. https://​doi.​org/​10.​1152/​ajpheart.​00870.​2007 CrossRef
40.
Zurück zum Zitat Mazovets OL, Trifonov IR, Katrukha AG, Bereznikova AV, Medvedeva MV, Deev AD, Gratsianksii NA (2008) Heart fatty acid binding protein in patients hospitalized because of worsening heart failure. Relation to prognosis of death. Kardiologiia 48:24–29PubMed Mazovets OL, Trifonov IR, Katrukha AG, Bereznikova AV, Medvedeva MV, Deev AD, Gratsianksii NA (2008) Heart fatty acid binding protein in patients hospitalized because of worsening heart failure. Relation to prognosis of death. Kardiologiia 48:24–29PubMed
51.
Zurück zum Zitat Avgerinou G, Tousoulis D, Siasos G, Oikonomou E, Maniatis K, Papageorgiou N, Paraskevopoulos T, Miliou A, Koumaki D, Latsios G, Therianiou A, Trikas A, Kampoli AM, Stefanadis C (2011) Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol 151:382–383. https://doi.org/10.1016/j.ijcard.2011.06.112 PubMedCrossRef Avgerinou G, Tousoulis D, Siasos G, Oikonomou E, Maniatis K, Papageorgiou N, Paraskevopoulos T, Miliou A, Koumaki D, Latsios G, Therianiou A, Trikas A, Kampoli AM, Stefanadis C (2011) Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol 151:382–383. https://​doi.​org/​10.​1016/​j.​ijcard.​2011.​06.​112 PubMedCrossRef
53.
Zurück zum Zitat Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ, Rossbacher JC, Moore IK, Regittnig W, Munoz DS, Kim JH, Shulman GI (2007) N-3 fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes 56:1034–1041. https://doi.org/10.2337/db06-1206 PubMedCrossRef Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ, Rossbacher JC, Moore IK, Regittnig W, Munoz DS, Kim JH, Shulman GI (2007) N-3 fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes 56:1034–1041. https://​doi.​org/​10.​2337/​db06-1206 PubMedCrossRef
60.
Zurück zum Zitat Czarnowska E, Turska-Kmiec A (2012) Current opinions on mechanisms of energetic abnormalities in heart. Significance of the PPARalpha expression and therapeutic objects. Kardiol Pol 70:1061–1067PubMed Czarnowska E, Turska-Kmiec A (2012) Current opinions on mechanisms of energetic abnormalities in heart. Significance of the PPARalpha expression and therapeutic objects. Kardiol Pol 70:1061–1067PubMed
62.
Zurück zum Zitat Brings S, Fleming T, Freichel M, Muckenthaler MU, Herzig S, Nawroth PP (2017) Dicarbonyls and advanced glycation end-products in the development of diabetic complications and targets for intervention. Int J Mol Sci 18. https://doi.org/10.3390/ijms18050984 Brings S, Fleming T, Freichel M, Muckenthaler MU, Herzig S, Nawroth PP (2017) Dicarbonyls and advanced glycation end-products in the development of diabetic complications and targets for intervention. Int J Mol Sci 18. https://​doi.​org/​10.​3390/​ijms18050984
64.
Zurück zum Zitat Kumari K, Sahib MK (1993) Susceptibility of different rat tissues to non-enzymatic protein glycosylation in experimental diabetes. Indian J Exp Biol 31:194–195PubMed Kumari K, Sahib MK (1993) Susceptibility of different rat tissues to non-enzymatic protein glycosylation in experimental diabetes. Indian J Exp Biol 31:194–195PubMed
65.
Zurück zum Zitat Nozynski J, Zakliczynski M, Konecka-Mrowka D, Zielinska T, Zakliczynska H, Nikiel B, Mlynarczyk-Liszka J, Mrowka A, Zembala-Nozynska E, Pijet M, Rdzanowska K, Lange D, Przybylski R, Zembala M (2012) Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Ann Transplant 17:53–61PubMedCrossRef Nozynski J, Zakliczynski M, Konecka-Mrowka D, Zielinska T, Zakliczynska H, Nikiel B, Mlynarczyk-Liszka J, Mrowka A, Zembala-Nozynska E, Pijet M, Rdzanowska K, Lange D, Przybylski R, Zembala M (2012) Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Ann Transplant 17:53–61PubMedCrossRef
69.
Zurück zum Zitat Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG (2001) Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104:1464–1470PubMedCrossRef Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG (2001) Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104:1464–1470PubMedCrossRef
70.
Zurück zum Zitat Tanaka S, Avigad G, Brodsky B, Eikenberry EF (1988) Glycation induces expansion of the molecular packing of collagen. J Mol Biol 203:495–505PubMedCrossRef Tanaka S, Avigad G, Brodsky B, Eikenberry EF (1988) Glycation induces expansion of the molecular packing of collagen. J Mol Biol 203:495–505PubMedCrossRef
74.
Zurück zum Zitat Striker LJ, Striker GE (1996) Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol Dial Transplant 11(Suppl 5):62–65PubMedCrossRef Striker LJ, Striker GE (1996) Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol Dial Transplant 11(Suppl 5):62–65PubMedCrossRef
78.
Zurück zum Zitat Willemsen S, Hartog JW, Hummel YM, van Ruijven MH, van der Horst IC, van Veldhuisen DJ, Voors AA (2011) Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur J Heart Fail 13:76–82. https://doi.org/10.1093/eurjhf/hfq168 PubMedCrossRef Willemsen S, Hartog JW, Hummel YM, van Ruijven MH, van der Horst IC, van Veldhuisen DJ, Voors AA (2011) Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur J Heart Fail 13:76–82. https://​doi.​org/​10.​1093/​eurjhf/​hfq168 PubMedCrossRef
79.
Zurück zum Zitat Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA, investigators B (2011) Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 13:899–908. https://doi.org/10.1093/eurjhf/hfr067 PubMedCrossRef Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, Hillege HL, Voors AA, investigators B (2011) Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 13:899–908. https://​doi.​org/​10.​1093/​eurjhf/​hfr067 PubMedCrossRef
80.
Zurück zum Zitat Wang LJ, Lu L, Zhang FR, Chen QJ, De Caterina R, Shen WF (2011) Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail 13:440–449. https://doi.org/10.1093/eurjhf/hfq231 PubMedCrossRef Wang LJ, Lu L, Zhang FR, Chen QJ, De Caterina R, Shen WF (2011) Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail 13:440–449. https://​doi.​org/​10.​1093/​eurjhf/​hfq231 PubMedCrossRef
84.
Zurück zum Zitat Davlouros PA, Gkizas V, Vogiatzi C, Giannopoulos G, Alexopoulos D, Deftereos S (2016) Calcium homeostasis and kinetics in heart failure. Med Chem 12:151–161PubMedCrossRef Davlouros PA, Gkizas V, Vogiatzi C, Giannopoulos G, Alexopoulos D, Deftereos S (2016) Calcium homeostasis and kinetics in heart failure. Med Chem 12:151–161PubMedCrossRef
85.
Zurück zum Zitat Hohendanner F, Ljubojevic S, MacQuaide N, Sacherer M, Sedej S, Biesmans L, Wakula P, Platzer D, Sokolow S, Herchuelz A, Antoons G, Sipido K, Pieske B, Heinzel FR (2013) Intracellular dyssynchrony of diastolic cytosolic [Ca(2)(+)] decay in ventricular cardiomyocytes in cardiac remodeling and human heart failure. Circ Res 113:527–538. https://doi.org/10.1161/CIRCRESAHA.113.300895 PubMedCrossRef Hohendanner F, Ljubojevic S, MacQuaide N, Sacherer M, Sedej S, Biesmans L, Wakula P, Platzer D, Sokolow S, Herchuelz A, Antoons G, Sipido K, Pieske B, Heinzel FR (2013) Intracellular dyssynchrony of diastolic cytosolic [Ca(2)(+)] decay in ventricular cardiomyocytes in cardiac remodeling and human heart failure. Circ Res 113:527–538. https://​doi.​org/​10.​1161/​CIRCRESAHA.​113.​300895 PubMedCrossRef
88.
91.
Zurück zum Zitat Petrova R, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto H (2002) Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34:1425–1431PubMedCrossRef Petrova R, Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto H (2002) Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol 34:1425–1431PubMedCrossRef
94.
Zurück zum Zitat Tuncay E, Okatan EN, Toy A, Turan B (2014) Enhancement of cellular antioxidant-defence preserves diastolic dysfunction via regulation of both diastolic Zn2+ and Ca2+ and prevention of RyR2-leak in hyperglycemic cardiomyocytes. Oxidative Med Cell Longev 2014:290381. https://doi.org/10.1155/2014/290381 CrossRef Tuncay E, Okatan EN, Toy A, Turan B (2014) Enhancement of cellular antioxidant-defence preserves diastolic dysfunction via regulation of both diastolic Zn2+ and Ca2+ and prevention of RyR2-leak in hyperglycemic cardiomyocytes. Oxidative Med Cell Longev 2014:290381. https://​doi.​org/​10.​1155/​2014/​290381 CrossRef
96.
100.
Zurück zum Zitat Baker DL, Dave V, Reed T, Periasamy M (1996) Multiple Sp1 binding sites in the cardiac/slow twitch muscle sarcoplasmic reticulum Ca2+-ATPase gene promoter are required for expression in Sol8 muscle cells. J Biol Chem 271:5921–5928PubMedCrossRef Baker DL, Dave V, Reed T, Periasamy M (1996) Multiple Sp1 binding sites in the cardiac/slow twitch muscle sarcoplasmic reticulum Ca2+-ATPase gene promoter are required for expression in Sol8 muscle cells. J Biol Chem 271:5921–5928PubMedCrossRef
103.
Zurück zum Zitat Tuncay E, Bitirim CV, Olgar Y, Durak A, Rutter GA, Turan B (2018) Zn(2+)-transporters ZIP7 and ZnT7 play important role in progression of cardiac dysfunction via affecting sarco(endo)plasmic reticulum-mitochondria coupling in hyperglycemic cardiomyocytes. Mitochondrion. https://doi.org/10.1016/j.mito.2017.12.011 Tuncay E, Bitirim CV, Olgar Y, Durak A, Rutter GA, Turan B (2018) Zn(2+)-transporters ZIP7 and ZnT7 play important role in progression of cardiac dysfunction via affecting sarco(endo)plasmic reticulum-mitochondria coupling in hyperglycemic cardiomyocytes. Mitochondrion. https://​doi.​org/​10.​1016/​j.​mito.​2017.​12.​011
106.
Zurück zum Zitat Olgar Y, Durak A, Tuncay E, Bitirim CV, Ozcinar E, Inan MB, Tokcaer-Keskin Z, Akcali KC, Akar AR, Turan B (2018) Increased free Zn(2+) correlates induction of sarco(endo)plasmic reticulum stress via altered expression levels of Zn(2+)-transporters in heart failure. J Cell Mol Med. https://doi.org/10.1111/jcmm.13480 Olgar Y, Durak A, Tuncay E, Bitirim CV, Ozcinar E, Inan MB, Tokcaer-Keskin Z, Akcali KC, Akar AR, Turan B (2018) Increased free Zn(2+) correlates induction of sarco(endo)plasmic reticulum stress via altered expression levels of Zn(2+)-transporters in heart failure. J Cell Mol Med. https://​doi.​org/​10.​1111/​jcmm.​13480
121.
Zurück zum Zitat Amato L, Paolisso G, Cacciatore F, Ferrara N, Ferrara P, Canonico S, Varricchio M, Rengo F (1997) Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 23:213–218PubMed Amato L, Paolisso G, Cacciatore F, Ferrara N, Ferrara P, Canonico S, Varricchio M, Rengo F (1997) Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 23:213–218PubMed
122.
Zurück zum Zitat Andersson C, Norgaard ML, Hansen PR, Fosbol EL, Schmiegelow M, Weeke P, Olesen JB, Raunso J, Jorgensen CH, Vaag A, Kober L, Torp-Pedersen C, Gislason GH (2010) Heart failure severity, as determined by loop diuretic dosages, predicts the risk of developing diabetes after myocardial infarction: a nationwide cohort study. Eur J Heart Fail 12:1333–1338. https://doi.org/10.1093/eurjhf/hfq160 PubMedCrossRef Andersson C, Norgaard ML, Hansen PR, Fosbol EL, Schmiegelow M, Weeke P, Olesen JB, Raunso J, Jorgensen CH, Vaag A, Kober L, Torp-Pedersen C, Gislason GH (2010) Heart failure severity, as determined by loop diuretic dosages, predicts the risk of developing diabetes after myocardial infarction: a nationwide cohort study. Eur J Heart Fail 12:1333–1338. https://​doi.​org/​10.​1093/​eurjhf/​hfq160 PubMedCrossRef
124.
125.
Zurück zum Zitat McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Guidelines ESCCfP (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847. https://doi.org/10.1093/eurheartj/ehs104 PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Guidelines ESCCfP (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787–1847. https://​doi.​org/​10.​1093/​eurheartj/​ehs104 PubMedCrossRef
127.
128.
Zurück zum Zitat Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS, Investigators G (2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292:2227–2236. https://doi.org/10.1001/jama.292.18.2227 PubMedCrossRef Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS, Investigators G (2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292:2227–2236. https://​doi.​org/​10.​1001/​jama.​292.​18.​2227 PubMedCrossRef
131.
Zurück zum Zitat Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527–550PubMedCrossRef Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527–550PubMedCrossRef
134.
Zurück zum Zitat Volker D, Fitzgerald P, Major G, Garg M (2000) Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol 27:2343–2346PubMed Volker D, Fitzgerald P, Major G, Garg M (2000) Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol 27:2343–2346PubMed
135.
Zurück zum Zitat Norell SE, Ahlbom A, Feychting M, Pedersen NL (1986) Fish consumption and mortality from coronary heart disease. Br Med J 293:426CrossRef Norell SE, Ahlbom A, Feychting M, Pedersen NL (1986) Fish consumption and mortality from coronary heart disease. Br Med J 293:426CrossRef
136.
Zurück zum Zitat Chrysohoou C, Metallinos G, Georgiopoulos G, Mendrinos D, Papanikolaou A, Magkas N, Pitsavos C, Vyssoulis G, Stefanadis C, Tousoulis D (2016) Short term omega-3 polyunsaturated fatty acid supplementation induces favorable changes in right ventricle function and diastolic filling pressure in patients with chronic heart failure; a randomized clinical trial. Vasc Pharmacol 79:43–50. https://doi.org/10.1016/j.vph.2016.01.005 CrossRef Chrysohoou C, Metallinos G, Georgiopoulos G, Mendrinos D, Papanikolaou A, Magkas N, Pitsavos C, Vyssoulis G, Stefanadis C, Tousoulis D (2016) Short term omega-3 polyunsaturated fatty acid supplementation induces favorable changes in right ventricle function and diastolic filling pressure in patients with chronic heart failure; a randomized clinical trial. Vasc Pharmacol 79:43–50. https://​doi.​org/​10.​1016/​j.​vph.​2016.​01.​005 CrossRef
137.
Zurück zum Zitat Heydari B, Abdullah S, Pottala JV, Shah R, Abbasi S, Mandry D, Francis SA, Lumish H, Ghoshhajra BB, Hoffmann U, Appelbaum E, Feng JH, Blankstein R, Steigner M, McConnell JP, Harris W, Antman EM, Jerosch-Herold M, Kwong RY (2016) Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL Randomized Clinical Trial. Circulation 134:378–391. https://doi.org/10.1161/CIRCULATIONAHA.115.019949 PubMedPubMedCentralCrossRef Heydari B, Abdullah S, Pottala JV, Shah R, Abbasi S, Mandry D, Francis SA, Lumish H, Ghoshhajra BB, Hoffmann U, Appelbaum E, Feng JH, Blankstein R, Steigner M, McConnell JP, Harris W, Antman EM, Jerosch-Herold M, Kwong RY (2016) Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL Randomized Clinical Trial. Circulation 134:378–391. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​115.​019949 PubMedPubMedCentralCrossRef
142.
Zurück zum Zitat Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, investigators Fs (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849–1861. https://doi.org/10.1016/S0140-6736(05)67667-2 PubMedCrossRef Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, investigators Fs (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849–1861. https://​doi.​org/​10.​1016/​S0140-6736(05)67667-2 PubMedCrossRef
143.
Zurück zum Zitat (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905–910 (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905–910
145.
Zurück zum Zitat Labinskyy V, Bellomo M, Chandler MP, Young ME, Lionetti V, Qanud K, Bigazzi F, Sampietro T, Stanley WC, Recchia FA (2007) Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure. J Pharmacol Exp Ther 321:165–171. https://doi.org/10.1124/jpet.106.116871 PubMedCrossRef Labinskyy V, Bellomo M, Chandler MP, Young ME, Lionetti V, Qanud K, Bigazzi F, Sampietro T, Stanley WC, Recchia FA (2007) Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure. J Pharmacol Exp Ther 321:165–171. https://​doi.​org/​10.​1124/​jpet.​106.​116871 PubMedCrossRef
147.
Zurück zum Zitat Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I (2002) Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci 103(Suppl 48):284S–288S. https://doi.org/10.1042/CS103S284S CrossRef Ogata T, Miyauchi T, Sakai S, Irukayama-Tomobe Y, Goto K, Yamaguchi I (2002) Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci 103(Suppl 48):284S–288S. https://​doi.​org/​10.​1042/​CS103S284S CrossRef
148.
150.
Zurück zum Zitat Hafstad AD, Khalid AM, Hagve M, Lund T, Larsen TS, Severson DL, Clarke K, Berge RK, Aasum E (2009) Cardiac peroxisome proliferator-activated receptor-alpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss. Cardiovasc Res 83:519–526. https://doi.org/10.1093/cvr/cvp132 PubMedCrossRef Hafstad AD, Khalid AM, Hagve M, Lund T, Larsen TS, Severson DL, Clarke K, Berge RK, Aasum E (2009) Cardiac peroxisome proliferator-activated receptor-alpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss. Cardiovasc Res 83:519–526. https://​doi.​org/​10.​1093/​cvr/​cvp132 PubMedCrossRef
154.
155.
Zurück zum Zitat Morgan EE, Rennison JH, Young ME, McElfresh TA, Kung TA, Tserng KY, Hoit BD, Stanley WC, Chandler MP (2006) Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. Am J Phys Heart Circ Phys 290:H1899–H1904. https://doi.org/10.1152/ajpheart.01014.2005 CrossRef Morgan EE, Rennison JH, Young ME, McElfresh TA, Kung TA, Tserng KY, Hoit BD, Stanley WC, Chandler MP (2006) Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. Am J Phys Heart Circ Phys 290:H1899–H1904. https://​doi.​org/​10.​1152/​ajpheart.​01014.​2005 CrossRef
162.
Zurück zum Zitat Madrid-Miller A, Moreno-Ruiz LA, Borrayo-Sanchez G, Almeida-Gutierrez E, Martinez-Gomez DF, Jauregui-Aguilar R (2010) Impact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trial. Cir Cir 78:229–237PubMed Madrid-Miller A, Moreno-Ruiz LA, Borrayo-Sanchez G, Almeida-Gutierrez E, Martinez-Gomez DF, Jauregui-Aguilar R (2010) Impact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trial. Cir Cir 78:229–237PubMed
165.
Zurück zum Zitat Sarma S (2012) Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits? Curr Mol Pharmacol 5:255–263PubMedCrossRef Sarma S (2012) Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits? Curr Mol Pharmacol 5:255–263PubMedCrossRef
169.
Zurück zum Zitat Tousoulis D, Psaltopoulou T, Androulakis E, Papageorgiou N, Papaioannou S, Oikonomou E, Synetos A, Stefanadis C (2015) Oxidative stress and early atherosclerosis: novel antioxidant treatment. Cardiovasc Drugs Ther sponsored by the International Society of Cardiovascular Pharmacotherapy 29:75–88. https://doi.org/10.1007/s10557-014-6562-5 PubMedCrossRef Tousoulis D, Psaltopoulou T, Androulakis E, Papageorgiou N, Papaioannou S, Oikonomou E, Synetos A, Stefanadis C (2015) Oxidative stress and early atherosclerosis: novel antioxidant treatment. Cardiovasc Drugs Ther sponsored by the International Society of Cardiovascular Pharmacotherapy 29:75–88. https://​doi.​org/​10.​1007/​s10557-014-6562-5 PubMedCrossRef
170.
171.
Zurück zum Zitat Lebovitz HE, Banerji MA (2001) Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 56:265–294PubMedCrossRef Lebovitz HE, Banerji MA (2001) Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 56:265–294PubMedCrossRef
172.
174.
Zurück zum Zitat Derosa G, Dangelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Cicero AF (2006) Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res 34:545–555. https://doi.org/10.1177/147323000603400513 PubMedCrossRef Derosa G, Dangelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Cicero AF (2006) Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res 34:545–555. https://​doi.​org/​10.​1177/​1473230006034005​13 PubMedCrossRef
175.
Zurück zum Zitat Kruszynska YT, Yu JG, Olefsky JM, Sobel BE (2000) Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 49:633–639PubMedCrossRef Kruszynska YT, Yu JG, Olefsky JM, Sobel BE (2000) Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 49:633–639PubMedCrossRef
177.
180.
Zurück zum Zitat Nakamura T, Matsuda T, Kawagoe Y, Ogawa H, Takahashi Y, Sekizuka K, Koide H (2004) Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metab Clin Exp 53:1382–1386PubMedCrossRef Nakamura T, Matsuda T, Kawagoe Y, Ogawa H, Takahashi Y, Sekizuka K, Koide H (2004) Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metab Clin Exp 53:1382–1386PubMedCrossRef
181.
Zurück zum Zitat Qayyum R, Adomaityte J (2006) A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens 8:19–28CrossRef Qayyum R, Adomaityte J (2006) A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens 8:19–28CrossRef
183.
187.
Zurück zum Zitat Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, Investigators PR (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289. https://doi.org/10.1016/S0140-6736(05)67528-9 PubMedCrossRef Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, Investigators PR (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289. https://​doi.​org/​10.​1016/​S0140-6736(05)67528-9 PubMedCrossRef
188.
Zurück zum Zitat Yue TL (2003) Cardioprotective effects of thiazolidinediones, peroxisome proliferator-activated receptor-gamma agonists. Drugs Today 39:949–960CrossRef Yue TL (2003) Cardioprotective effects of thiazolidinediones, peroxisome proliferator-activated receptor-gamma agonists. Drugs Today 39:949–960CrossRef
189.
Zurück zum Zitat Yue Tl TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104:2588–2594PubMedCrossRef Yue Tl TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104:2588–2594PubMedCrossRef
193.
Zurück zum Zitat Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A (2002) Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106:3126–3132PubMedCrossRef Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A (2002) Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106:3126–3132PubMedCrossRef
195.
196.
Zurück zum Zitat Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, Zambanini A, Wilding JP (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 49:1696–1704. https://doi.org/10.1016/j.jacc.2006.10.077 PubMedCrossRef Dargie HJ, Hildebrandt PR, Riegger GA, McMurray JJ, McMorn SO, Roberts JN, Zambanini A, Wilding JP (2007) A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 49:1696–1704. https://​doi.​org/​10.​1016/​j.​jacc.​2006.​10.​077 PubMedCrossRef
197.
Zurück zum Zitat Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K (2001) Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104:1670–1675PubMedCrossRef Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K (2001) Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 104:1670–1675PubMedCrossRef
199.
Zurück zum Zitat Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS (2003) Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev 19:487–493. https://doi.org/10.1002/dmrr.410 PubMedCrossRef Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS (2003) Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev 19:487–493. https://​doi.​org/​10.​1002/​dmrr.​410 PubMedCrossRef
201.
Zurück zum Zitat Zhao SM, Li HW, Guo CY, Shen LH (2010) Cardiac fibrosis in diabetic rats: regulation and mechanism of activation of the PPARgamma signal pathway. Chin J Physiol 53:262–267PubMedCrossRef Zhao SM, Li HW, Guo CY, Shen LH (2010) Cardiac fibrosis in diabetic rats: regulation and mechanism of activation of the PPARgamma signal pathway. Chin J Physiol 53:262–267PubMedCrossRef
205.
Zurück zum Zitat Naka KK, Pappas K, Papathanassiou K, Papamichael ND, Kazakos N, Kanioglou C, Makriyiannis D, Katsouras CS, Liveris K, Tsatsoulis A, Michalis LK (2010) Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue Doppler imaging study. Cardiovasc Diabetol 9:57. https://doi.org/10.1186/1475-2840-9-57 PubMedPubMedCentralCrossRef Naka KK, Pappas K, Papathanassiou K, Papamichael ND, Kazakos N, Kanioglou C, Makriyiannis D, Katsouras CS, Liveris K, Tsatsoulis A, Michalis LK (2010) Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue Doppler imaging study. Cardiovasc Diabetol 9:57. https://​doi.​org/​10.​1186/​1475-2840-9-57 PubMedPubMedCentralCrossRef
206.
212.
Zurück zum Zitat Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR (1998) Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273:2161–2168PubMedCrossRef Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR (1998) Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273:2161–2168PubMedCrossRef
213.
216.
Zurück zum Zitat Claessen BE, Stone GW, Mehran R, Witzenbichler B, Brodie BR, Wohrle J, Witkowski A, Guagliumi G, Zmudka K, Henriques JP, Tijssen JG, Sanidas EA, Chantziara V, Hakim D, Leon S, Xu K, Dangas GD (2012) Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. J Thromb Thrombolysis 34:165–179. https://doi.org/10.1007/s11239-012-0706-x PubMedCrossRef Claessen BE, Stone GW, Mehran R, Witzenbichler B, Brodie BR, Wohrle J, Witkowski A, Guagliumi G, Zmudka K, Henriques JP, Tijssen JG, Sanidas EA, Chantziara V, Hakim D, Leon S, Xu K, Dangas GD (2012) Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. J Thromb Thrombolysis 34:165–179. https://​doi.​org/​10.​1007/​s11239-012-0706-x PubMedCrossRef
218.
Zurück zum Zitat Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM (2005) Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28:1680–1689PubMedCrossRef Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM (2005) Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28:1680–1689PubMedCrossRef
220.
Zurück zum Zitat Sena S, Rasmussen IR, Wende AR, McQueen AP, Theobald HA, Wilde N, Pereira RO, Litwin SE, Berger JP, Abel ED (2007) Cardiac hypertrophy caused by peroxisome proliferator-activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling. Endocrinology 148:6047–6053. https://doi.org/10.1210/en.2006-1559 PubMedCrossRef Sena S, Rasmussen IR, Wende AR, McQueen AP, Theobald HA, Wilde N, Pereira RO, Litwin SE, Berger JP, Abel ED (2007) Cardiac hypertrophy caused by peroxisome proliferator-activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling. Endocrinology 148:6047–6053. https://​doi.​org/​10.​1210/​en.​2006-1559 PubMedCrossRef
221.
Zurück zum Zitat Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R (2004) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256–263PubMedCrossRef Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R (2004) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27:256–263PubMedCrossRef
Metadaten
Titel
Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance
verfasst von
Evangelos Oikonomou
Konstantinos Mourouzis
Petros Fountoulakis
Georgios Angelos Papamikroulis
Gerasimos Siasos
Alexis Antonopoulos
Georgia Vogiatzi
Sotiris Tsalamadris
Manolis Vavuranakis
Dimitris Tousoulis
Publikationsdatum
17.02.2018
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 3/2018
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-018-9682-3

Weitere Artikel der Ausgabe 3/2018

Heart Failure Reviews 3/2018 Zur Ausgabe

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.